摘要目的 观察重组人血管内皮抑制素(恩度)联合GP方案治疗晚期非小细胞肺癌(NSCLC)的疗效和毒副反应.方法 经病理学或细胞学检查证实的37例晚期NSCLC患者,包括鳞癌21例,腺癌16例.吉西他滨1 000 mg/m2,静脉滴注,第1、8天;顺铂80 mg/m2,静脉滴注,分3 d给予;恩度15 mg/d,静脉滴注,第1～14天,21 d为1个周期.每例患者至少完成2个周期.根据WHO疗效评定及毒副反应分级标准,观察其近期疗效、疾病进展时间及毒副反应.结果 37例晚期NSCLC患者中,CR 1例,PR 15例,SD 14例,PD 7例,总有效率(CR+PR)43.2%.中位疾病进展时间为5.2个月.毒副反应主要为血液学、消化道毒性,Ⅲ～Ⅳ度中性粒细胞减少占32.4%,Ⅲ～Ⅳ度血小板减少占20.5%,未见与化疗相关的死亡.结论 恩度联合GP方案治疗晚期NSCLC近期客观疗效较高,安全性好.

abstractsObjective To observe the efficacy and safety of recombinant human endostatin injection (en-dostar) combined with GP(gemcitabine plus cisplatin)regimen in patients with advanced non- small cell lung cancer (NSCLC). Methods Thirty seven histologically confirmed advanced NSCLC patients were enrolled in the group. The patients were administered with endostar 15 mg from day 1 to 14,gemcitabine 1 000 mg/m2 day 1 and 8,cisplatin 80 mg/m2 on days devided into 1 - 3, repeated 21 days. Each patient should complete two cycles. Results 37 patients were valuable for response. One patient achieved complete response(CR), 15 partial response(PR), 14 stable disease (SD) ,and 7 were found to have disease progression(PD). The total response rate was 43.2% ,median TIP was 5.2 months. The main toxicities was leukopenia. There was no treatment-related death in this series. Conclusion En-dostar combined GP regimen was effective and safe in treatment of advanced NSCLC.